DE60220290D1 - Pyridinderivate als inhibitoren der raf-kinase - Google Patents

Pyridinderivate als inhibitoren der raf-kinase

Info

Publication number
DE60220290D1
DE60220290D1 DE60220290T DE60220290T DE60220290D1 DE 60220290 D1 DE60220290 D1 DE 60220290D1 DE 60220290 T DE60220290 T DE 60220290T DE 60220290 T DE60220290 T DE 60220290T DE 60220290 D1 DE60220290 D1 DE 60220290D1
Authority
DE
Germany
Prior art keywords
inhibitors
raf kinase
pyridine derivatives
migraine
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220290T
Other languages
English (en)
Other versions
DE60220290T2 (de
Inventor
Mark James Bamford
David Kenneth Dean
Antoinette Naylor
Andrew Kenneth Takle
David Matthew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60220290D1 publication Critical patent/DE60220290D1/de
Publication of DE60220290T2 publication Critical patent/DE60220290T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
DE60220290T 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase Expired - Fee Related DE60220290T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121490.7A GB0121490D0 (en) 2001-09-05 2001-09-05 Ciompounds
GB0121490 2001-09-05
PCT/EP2002/009946 WO2003022840A1 (en) 2001-09-05 2002-09-05 Pyridine derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60220290D1 true DE60220290D1 (de) 2007-07-05
DE60220290T2 DE60220290T2 (de) 2008-01-31

Family

ID=9921558

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220290T Expired - Fee Related DE60220290T2 (de) 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase

Country Status (11)

Country Link
US (1) US7452906B2 (de)
EP (1) EP1423384B1 (de)
JP (1) JP2005504794A (de)
AT (1) ATE362929T1 (de)
CY (1) CY1106766T1 (de)
DE (1) DE60220290T2 (de)
DK (1) DK1423384T3 (de)
ES (1) ES2284939T3 (de)
GB (1) GB0121490D0 (de)
PT (1) PT1423384E (de)
WO (1) WO2003022840A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1623601A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Novel compounds
ES2218391T3 (es) * 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022837A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
IL163688A0 (en) 2002-02-28 2005-12-18 Astrazeneca Ab 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents
CA2477379A1 (en) 2002-02-28 2003-09-04 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1951728A4 (de) * 2005-11-04 2011-04-20 Glaxosmithkline Llc Thienopyridine als inhibitoren von b-raf-kinase
EP2170830B1 (de) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZOSULFONAMID-VERBINDUNGEN ALS Raf-KINASE-MODULATOREN
JP2011513332A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
KR20100117686A (ko) 2008-02-29 2010-11-03 어레이 바이오파마 인크. 피라졸[3,4-ｂ]피리딘 ｒａｆ 저해물질
WO2011025940A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2772575A1 (en) 2009-08-28 2011-03-03 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
EP2470541A1 (de) 2009-08-28 2012-07-04 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
CA2771895A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2013503187A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
EP2470532A1 (de) 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo-[3, 4-b]pyridin-zusammensetzungen zur raf-kinase-hemmung
US8907098B2 (en) * 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
MX2016008201A (es) * 2013-12-20 2017-04-27 Biomed Valley Discoveries Inc Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
CA2423154A1 (en) * 2000-09-21 2002-03-28 David Kenneth Dean Imidazole derivatives as raf kinase inhibitors

Also Published As

Publication number Publication date
EP1423384B1 (de) 2007-05-23
EP1423384A1 (de) 2004-06-02
PT1423384E (pt) 2007-08-24
DE60220290T2 (de) 2008-01-31
CY1106766T1 (el) 2012-05-23
WO2003022840A1 (en) 2003-03-20
ES2284939T3 (es) 2007-11-16
GB0121490D0 (en) 2001-10-24
US20040235843A1 (en) 2004-11-25
US7452906B2 (en) 2008-11-18
DK1423384T3 (da) 2007-09-24
ATE362929T1 (de) 2007-06-15
JP2005504794A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
DE60220290D1 (de) Pyridinderivate als inhibitoren der raf-kinase
ATE300529T1 (de) Imidazolderivate als raf-kinase-inhibitoren
ATE517896T1 (de) P38-kinase-inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
ATE454152T1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
ATE408601T1 (de) Fredericamycin-derivate
NO20082414L (no) Inhibitorer av AKT-aktivitet
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
EA200700098A1 (ru) Производные 4-арилморфолин-3-она, их получение и их применение в терапии
UA96570C2 (ru) Лиганды н3-рецептора гистамина и их терапевтические применения
DK1620547T3 (da) Stabiliserede aptamere til blodpladeafledt vækstfaktor og anvendelse deraf som onkologibehandling

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BAMFORD, MARK, JAMES, HARLOW, ESSEX CM19 5AW, GB

Inventor name: DEAN, DAVID, KENNETH, HARLOW ESSEX CM19 5AW, GB

Inventor name: NAYLOR, ANTOINETTE, HARLOW ESSEX CM19 5AW, GB

Inventor name: TAKLE, ANDREW, KENNETH, HARLOW ESSEX CM19 5AW, GB

Inventor name: WILSON, DAVID, MATTHEW, HARLOW ESSEX CM19 5AW, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee